Sign In
Buy KZR
$7.29
+0 (+0%)
At Close: Jun 10, 2026
Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)
02:20am, Wednesday, 03'rd Dec 2025
Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 12'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated dise
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00
01:14am, Monday, 20'th Oct 2025
Kezar Life Sciences, Inc. (NASDAQ: KZR - Get Free Report) has earned an average rating of "Reduce" from the six brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts h
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet n
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy
01:01pm, Wednesday, 17'th Sep 2025
Kezar Life Sciences (KZR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
04:01pm, Thursday, 28'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 13'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
04:01pm, Wednesday, 28'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
01:06pm, Tuesday, 27'th May 2025
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Tuesday, 13'th May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
Kezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)
06:54pm, Tuesday, 25'th Mar 2025
Kezar Life Sciences, Inc. (NASDAQ:KZR ) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call March 25, 2025 8:00 AM ET Company Participants Chris Kirk - Chief Executive Officer & C
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immun
